The UK charity for Waldenstrom’s macroglobulinaemia – a rare type of blood cancer

Support Line: 0300 373 8500

Showing only trials that are Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Studying the long-term effects of Ibrutinib in people who were on previous trials for the drug that have now closed

Expected to end: 29/01/2027

Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia (RAINBOW)

Is ibrutinib and rituximab a more effective first-line treatment than the current standard first-line treatment for people with WM?

Expected to end: 01/03/2030

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Studying long-term data for Venetoclax in people who were previously taking the drug on other trials

Expected to end: 01/02/2026

The UK charity for Waldenstrom’s Macroglobulinaemia

WMUK, Foden House, 47 London Road,
Alderley Edge, Cheshire, SK9 7JT

Registered as a charity in England and Wales (1187121).

A company limited by guarantee in England and Wales (12358324).

Privacy & Cookies

Support Line: 0300 373 8500

General enquiries: 0300 303 5870